Literature DB >> 21247820

Polymorphisms in arsenic(+III oxidation state) methyltransferase (AS3MT) predict gene expression of AS3MT as well as arsenic metabolism.

Karin Engström1, Marie Vahter, Simona Jurkovic Mlakar, Gabriela Concha, Barbro Nermell, Rubhana Raqib, Alejandro Cardozo, Karin Broberg.   

Abstract

BACKGROUND: Arsenic (As) occurs as monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA) in humans, and the methylation pattern demonstrates large interindividual differences. The fraction of urinary MMA is a marker for susceptibility to As-related diseases.
OBJECTIVES: We evaluated the impact of polymorphisms in five methyltransferase genes on As metabolism in two populations, one in South America and one in Southeast Asia. The methyltransferase genes were arsenic(+III oxidation state) methyltransferase (AS3MT), DNA-methyltransferase 1a and 3b (DNMT1a and DNMT3b, respectively), phosphatidylethanolamine N-methyltransferase (PEMT), and betaine-homocysteine methyltransferase (BHMT). AS3MT expression was analyzed in peripheral blood.
METHODS: Subjects were women exposed to As in drinking water in the Argentinean Andes [n = 172; median total urinary As (U-As), 200 µg/L] and in rural Bangladesh (n = 361; U-As, 100 µg/L; all in early pregnancy). Urinary As metabolites were measured by high-pressure liquid chromatography/inductively coupled plasma mass spectrometry. Polymorphisms (n = 22) were genotyped with Sequenom, and AS3MT expression was measured by quantitative real-time polymerase chain reaction using TaqMan expression assays.
RESULTS: Six AS3MT polymorphisms were significantly associated with As metabolite patterns in both populations (p ≤ 0.01). The most frequent AS3MT haplotype in Bangladesh was associated with a higher percentage of MMA (%MMA), and the most frequent haplotype in Argentina was associated with a lower %MMA and a higher percentage of DMA. Four polymorphisms in the DNMT genes were associated with metabolite patterns in Bangladesh. Noncoding AS3MT polymorphisms affected gene expression of AS3MT in peripheral blood, demonstrating that one functional impact of AS3MT polymorphisms may be altered levels of gene expression.
CONCLUSIONS: Polymorphisms in AS3MT significantly predicted As metabolism across these two very different populations, suggesting that AS3MT may have an impact on As metabolite patterns in populations worldwide.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21247820      PMCID: PMC3040604          DOI: 10.1289/ehp.1002471

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


Millions of people around the world are exposed to high concentrations of arsenic (As) in drinking water, and these exposures are associated with a number of adverse health effects (International Agency for Research on Cancer 2004; National Research Council 2001). There is a marked individual variability in As metabolism, as measured by the distribution of inorganic As (iAs) and the main methylated metabolites monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA) in urine (Vahter 2002). Several studies have shown an association between an increased fraction of MMA in urine, probably reflecting the highly toxic MMAIII in the tissues, and an increased risk of various As-related adverse health effects (Chen et al. 2005; Chung et al. 2009; Lindberg et al. 2008; Tseng 2007). As is metabolized by a series of reduction and methylation reactions. S-Adenosyl methionine (SAM) is the main methyl donor, implying that As methylation is dependent on factors influencing one-carbon metabolism (Vahter 2002). As(+III oxidation state) methyltransferase (AS3MT) methylates As (Lin et al. 2002). We previously reported an unusual metabolism of As in a mainly indigenous population in the Argentinean Andes, with a lower percentage of MMA and a higher percentage of DMA compared with most other populations (Vahter et al. 1995). This is thought to be partly due to their high frequencies of AS3MT alleles associated with a lower percentage of MMA (%MMA) and higher percentage of DMA (%DMA) (Schläwicke Engström et al. 2007, 2009). The importance of AS3MT polymorphisms for As metabolism has also been also emphasized in other studies, both for noncoding variants (Agusa et al. 2009; Meza et al. 2005; Valenzuela et al. 2009) and for the exonic variant Met287Thr (Hernandez et al. 2008; Lindberg et al. 2007b; Valenzuela et al. 2009). However, there are few data on influential genetic variants in Bangladesh, where about 50 million people drink water with elevated As concentrations and where the inhabitants have shown an efficient methylation of As to DMA, despite prevalent malnutrition, which is likely to impair one-carbon metabolism (Li et al. 2008). Functional data for AS3MT polymorphisms are scarce, apart from a few studies on the Met287Thr variant (Drobna et al. 2004; Wood et al. 2006). Polymorphisms in the promoter and intronic regions may affect the expression of the AS3MT gene, which in turn is likely to affect the metabolite pattern. The methylation of As may partly be an AS3MT-independent process, because methylated As species have been found in As3mt-knockout mice, albeit a lower fraction than found in As3mt wild-type mice (Drobna et al. 2009). This may be explained by an As-methylating capacity of other methyltransferases. Such candidates could be the DNA methyltransferases (DNMT1a, DNMT3b). DNMTs and AS3MT use SAM as a methyl donor, and there are several parallel characteristics of As methylation and DNA methylation (Vahter 2007). Several different enzymes are involved in the one-carbon metabolism that generates SAM. For example, the phosphatidylethanolamine N-methyltransferase (PEMT) and betaine-homocysteine methyltransferase (BHMT) may influence As metabolism either by regulating the efficiency of the one carbon metabolism or by direct methylation of As. In this study, we evaluated the impact of polymorphisms in the above-mentioned methyltransferases (AS3MT, DNMT1a, DNMT3b, PEMT, and BHMT) on As metabolism in two different female populations: in the Andean part of northern Argentina and in rural Bangladesh. Both populations are known to have a wide range of exposure to As in drinking water (Concha et al. 2006; Schläwicke Engström et al. 2007; Vahter et al. 2006), and both populations show efficient methylation of As (Li et al. 2008; Vahter et al. 1995). Furthermore, we investigated the association between AS3MT polymorphisms and AS3MT gene expression in peripheral blood (Argentina), and the association between AS3MT gene expression and As metabolite pattern.

Materials and Methods

Study areas and populations

The study participants in Argentina were mainly women from San Antonio de los Cobres (SAC), a village in the northern Argentinean Andes. All subjects in SAC consumed drinking water from the same source; this water contained about 200 μg As/L, with small variations over time (Concha et al. 2006). To achieve a wider range of exposure, we also included in the study women from three nearby villages: Tolar Grande (3.5 μg As/L in drinking water; n = 21), Olacapato (12 μg As/L; n = 9), and Salar de Pocitos (73 μg As/L; n = 5). The study subjects in these three villages were very similar to the study subjects from SAC regarding ethnicity and socioeconomic factors. In total, urine and blood samples were collected from 176 women (not first-degree relatives) in 2008 (172 of which had both metabolite and genotyping data). The samples did not overlap with the women from the same region included in our earlier studies (Schläwicke Engström et al. 2007, 2009). The Bangladeshi women studied were from a longitudinal mother–child study of As-related health effects in Matlab, a rural area 53 km southeast of Dhaka. This study group is part of a large, population-based, randomized food and micronutrient supplementation trial in pregnancy (Maternal and Infant Nutrition Interventions in Matlab MINIMat). The study group and sampling procedures were described in detail by Li et al. (2008) and Vahter et al. (2006). Urine and blood were sampled in early pregnancy, urine during gestational week 8, and blood during gestational week 14, on average. From the 2,119 women who were enrolled during 2002, 500 women were randomly chosen for the present study. In total, 440 of the 500 women remained in the trial to receive micronutrient supplementation (no supplementation had been received before the sampling of urine), and 408 of those women provided a blood sample. Of these, urine for gestational week 8 was available for 361 individuals. The Ethical Review Committee of the International Centre for Diarrhoeal Disease Research, Bangladesh; the Health Ministry of Salta (Argentina); and the Ethics Committee of the Karolinska Institutet (Sweden) approved this study. Oral and written informed consent regarding sample collection was obtained from all participants in Argentina and Bangladesh. The results of the present study were evaluated blind for the individuals’ identity, and none of the participants will receive feedback regarding their own results.

Assessment of As exposure

Exposure to iAs was assessed by the total concentration of As metabolites in urine (U-As; sum of iAs, MMA, and DMA). Speciation of As metabolites in urine was performed using high-pressure liquid chromatography (HPLC) hyphenated with hydride generation and inductively coupled plasma mass spectrometry (ICPMS) (Agilent 1100 series system, Agilent 7500ce; Agilent Technologies, Tokyo, Japan, and Waldbronn, Germany), employing adequate quality control (Lindberg et al. 2007a; Schläwicke Engström et al. 2007). As concentrations were adjusted to the mean specific gravity for each population (1.020 g/mL in Argentina and 1.012 g/mL in Bangladesh), measured by a hand refractometer (Atago, Tokyo, Japan).

Genotyping

DNA was isolated from peripheral blood samples from both groups of subjects, and genotyping was performed by Swegene’s DNA Facility at Malmö University Hospital (Malmö, Sweden) using Sequenom technology (San Diego, CA, USA). Genotyped polymorphisms (22 polymorphisms in five methyltransferases) are shown in Supplemental Material, Table 1 (doi:10.1289/ehp.1002471).

Gene expression

We analyzed expression of the AS3MT gene (which covers 11 exons) by quantitative real-time polymerase chain reaction (qPCR) assays in peripheral blood samples from participants in Argentina. The rationale for the gene expression analyses was to evaluate whether the AS3MT polymorphisms affected gene expression, and if their possible effect on gene expression was due to alternative splicing of AS3MT. To evaluate potential alternative splicing, we ran qPCR assays for four different gene segments. If there was an alternative splicing of the gene, we assumed that the polymorphism that was closest to the amplified region was more likely to have an effect on the splicing of the nearby segments than those situated farther from the amplified region. The assays covered segments near the polymorphisms rs3740400 [assay 1: Taqman assay Hs00960536_g1, exons 1–2; polymorphism numbers from the National Center for Biotechnology Information (NCBI 2010b)], rs3740393 (assay 2: Hs00960529_m1, exons 5–6), and rs3740390 (assay 3: Hs00960532_g1, exons 8–9; all from Applied Biosystems, Foster City, CA, USA) and polymorphism rs1046778 [assay 4: 3′ untranslated region, base pairs 37,166–37,264 in AY817668 (NCBI 2010a)], using Applied Biosystems’ Assays-by-Design. We also evaluated whether AS3MT polymorphisms were associated with the expression of cyclin M2 (CNNM2; Hs00929648_m1, exons 1–2), which is located 16,500 base pairs from the AS3MT 3′ end, with rs1046778 as the closest polymorphism. For each gene expression assay, we tested associations with the genotype of the closest polymorphism in subsets of the total population that included approximately equal numbers of women with each of the three possible genotypes for that polymorphism [n per assay = 27–29; matched on a group level for age, weight, body mass index (BMI), U-As, and %MMA]. We repeated the analysis of assay 4 on a larger number of subjects with samples available, matched for age, weight, BMI, and U-As (n = 55). Peripheral blood was collected in PAX tubes (PreAnalytiX GmbH, Hombrechtikon, Switzerland), and all samples were frozen and stored at −20°C, after no more than 24 hr at room temperature after sampling. RNA was extracted with the PAXgene Blood RNA Kit (PreAnalytiX) and stored at −80°C. RNA concentration and purity were evaluated on a NanoDrop spectrophotometer (Thermo Scientific, Wilmington, DE, USA; for all samples, 260/280 nm mean optical density ratio = 2.3; range, 1.7–3.3), and RNA integrity (RIN) was evaluated on a Bioanalyzer 2100 (Agilent, Santa Clara, CA, USA; for 17 samples, mean RIN = 8.5; range, 7.6–9.1). For reverse transcription, we used the High Capacity RNA-to-cDNA Kit (Applied Biosystems). Preamplification for AS3MT was performed before qPCR using TaqMan PreAmp MasterMix (Applied Biosystems). AS3MT expression was normalized to hypoxanthine phosphoribosyltransferase 1 (HPRT1) and TATA-binding protein (TBP). HPRT1 and TBP were quantified using SYBR Green PCR Master Mix (Applied Biosystems) in nonpreamplified cDNA. The qPCR (20 μL reaction) was run under standard conditions on an ABI7900 instrument (Applied Biosystems) and performed in triplicate with a negative control included for each assay. Samples with an SD < 0.2 for the threshold cycle (CT) value were accepted. CT values of each sample were normalized to the mean CT value of each reference gene (ΔCT = AS3MT CT − reference gene CT). The ΔCT values were converted to a linear form using the term 2−ΔCT. The coefficients of variance for the mean CT values (2−CT) for all samples were 22% for HPRT1 and 32% for TBP, and we found no difference in expression between individuals with high and low U-As. We reran assay 4 for the 55 individuals to evaluate repeatability. The Pearson product-moment correlation coefficient (r) for the two runs was 0.99.

Statistical analyses

The study groups from Argentina and Bangladesh were analyzed separately. Deviations from Hardy-Weinberg equilibrium were tested using chi-square analysis. We performed linkage disequilibrium (LD) analysis using Haploview (Barrett et al. 2005). Haplotypes were inferred using PHASE software (Stephens and Donnelly 2003). In consideration of normally distributed residuals, the percentage of iAs (%iAs), %MMA, and total U-As were natural log (ln)-transformed for both study populations in all analyses. Associations between genotypes or haplotypes (independent variables) and urinary As metabolites (dependent variables: %iAs, %MMA, and %DMA) were analyzed by one-way analysis of variance. For each metabolite (dependent variables), we used a multivariable regression model (using the general linear model) that included genotype or haplotype (as categorical variables) and ln(U-As) (as a continuous and independent variable) to derive p-values for associations of genotypes or haplotypes with each metabolite. Additionally, for each metabolite, we used a multivariable regression model that included genotype or haplotype, ln(U-As), and adjustments for other variables. For each metabolite, all potentially influential independent variables were tested in univariate analyses, and those with p < 0.2 were included in the latter multivariable regression model. The potentially influential variables tested for the Argentinean study group were body weight, BMI, age, parity (all modeled as continuous variables), and coca use (yes/no), whereas those for the Bangladeshi study group were gestational week, body weight, BMI, age, and parity (all modeled as continuous variables). Each polymorphism was modeled as a categorical variable (zero, one, or two alleles). When the frequency of a homozygous genotype was very low (one to three individuals), the group was pooled with the heterozygotes. Haplotypes were also modeled as categorical variables (zero, one, or two copies of the haplotype). The genotype or haplotype associated with a low %MMA and a high %DMA was used as the reference genotype, because the aim was to discover which genotypes are associated with high fractions of MMA, a risk factor for As-related health effects. Observed geometric or arithmetic mean percent metabolite values are reported according to genotype for polymorphisms that were significantly associated with one or more metabolites (p < 0.05) in models adjusted for ln(U-As) only or in models adjusted for ln(U-As) and other variables. Observed geometric or arithmetic mean percent metabolite values are also reported for the most common AS3MT haplotypes. We used models for hypothesis testing only, and no model-based estimates are reported. We evaluated associations of AS3MT genotype with AS3MT gene expression using the nonparametric Kruskal-Wallis test. The association between gene expression in assay 4 and As the metabolite pattern in urine was evaluated using Spearman’s rank correlation coefficient (rs). All statistical analyses were performed using SPSS (version 17; SPSS Inc., Chicago, IL, USA). We considered p < 0.05 to be statistically significant.

Results

General characteristics

All polymorphisms were in Hardy-Weinberg equilibrium except for DNMT1a rs2228611 in Argentina (χ2 = 4.9, p = 0.03; in Bangladesh, χ2 = 0.4, p 0.52). Descriptive data for both study groups are presented in Table 1. No smokers were included in the study groups. Compared with women in Bangladesh, women in Argentina had U-As about twice as high (median, 200 μg/L; Bangladesh median, 100), lower %MMA (7.9% vs. 10%), and higher %DMA (80 vs. 75%). The U-As range was wide in both populations (10–1,200 in Argentina; 5–1,200 in Bangladesh).
Table 1

Descriptive data for the study populations.

Argentina
Bangladesh
VariablenMedian90th–10th percentilenMedian90th/10th percentile
U-As (μg/L)a17220027–45036110021–390
iAs (%)172124.9–21361147–24
MMA (%)1727.94.6–12361105–17
DMA (%)1728069–893617562–85
Age (years)1723420–583612619–35
Weight (kg)1725746–753594437–53
Height (cm)172152145–159361150144–158
BMI (kg/m2)1722420–323591917–24
Parity16831–836010–4
Coca use (%)17246NA

NA, not applicable.

Adjusted for specific weight.

AS3MT genotype analysis

The seven noncoding AS3MT polymorphisms had completely different allelic frequencies in the two study groups [see Supplemental Material, Table 1 (doi:10.1289/ehp.1002471)]. In Argentina, all AS3MT polymorphisms, except for rs11191439 (Met287Thr), showed strong LD (R2 between 0.82 and 0.98; see Supplemental Material, Figure 1). In Bangladesh, we detected two LD clusters: one cluster with rs3740400, rs10748835, and rs1046778 (cluster 1) and one cluster with rs3740393, rs3740390, and rs11191453 (cluster # 2) (see Supplemental Material, Figure 1). The polymorphism rs11191439 showed no LD with any of the other AS3MT polymorphisms evaluated in either study population. In Argentina, all AS3MT polymorphisms, except for the nonsynonymous rs11191439, were significantly associated with the metabolite pattern, and for each polymorphism the allele associated with lower %iAs, lower %MMA, and higher %DMA was the most common (Table 2). In Bangladesh, all AS3MT polymorphisms except rs7085104 were significantly associated with the metabolite pattern. However, patterns of associations varied between the two LD clusters: Polymorphisms in cluster 1 were significantly associated with %MMA but not %iAs or %DMA, whereas polymorphisms in cluster 2 were significantly associated with %iAs and %DMA but not %MMA. In most cases, the alleles associated with lower %MMA or lower %iAs and higher %DMA were the less frequent ones in Bangladesh.
Table 2

Observed mean valuesa for As metabolites according to genotype for polymorphisms that were significant predictors of As metabolites in the regression models.

Gene/rs number, genotypebArgentina
Bangladesh
n%iAs%MMA%DMAn%iAs%MMA%DMA
AS3MT

rs7085104

 GG939.67.181.23013.79.774.5
 GA6211.78.677.614713.710.273.5
 AA1514.210.373.518213.49.574.3
p-Value 1c0.030.0010.0010.890.140.58
p-Value 2d0.0510.0020.0020.850.140.58

rs3740400e

 CC939.67.181.27114.18.874
 CA6111.88.577.518013.610.273.7
 AA1514.210.373.510313.39.774.6
p-Value 10.0270.001< 0.0010.740.0080.51
p-Value 20.0580.0030.0030.730.0080.51

rs3740393f

 CC859.26.981.91310.87.979.8
 GC68128.777.2105129.276.8
 GG1714.71073.324014.510.172.5
p-Value 10.003< 0.001< 0.0010.0030.130.001
p-Value 20.0070.001< 0.0010.0030.130.001

rs3740390f

 AA849.36.981.81111.37.879.4
 AG6911.98.777.49412.29.476.5
 GG1714.71073.225514.21072.9
p-Value 10.006< 0.001< 0.0010.0250.150.004
p-Value 20.0180.001< 0.0010.0340.150.005

rs11191439

 MetMet16310.77.879.431313.29.774.6
 MetThr612.610.275.54216.71169
p-Value 10.860.220.450.0040.086< 0.001
p-Value 20.670.10.260.0050.0860.001

rs11191453f

 CC839.36.981.91111.37.879.4
 CT71128.777.39312.29.676.3
 TT1714.71073.325014.31072.8
p-Value 10.004< 0.001< 0.0010.0150.170.004
p-Value 20.007< 0.001< 0.0010.0150.170.005

rs10748835e

 AA939.67.181.36714.48.573.9
 AG62128.677.318913.210.274.2
 GG1514.210.373.59514.11073.4
p-Value 10.0140.001< 0.0010.380.0010.94
p-Value 20.0350.0010.0020.390.0010.97

rs1046778e

 CC879.36.981.94513.17.976.5
 CT6912.18.777.218313.19.674.6
 TT1514.210.373.513214.310.772.4
p-Value 10.005< 0.001< 0.0010.38< 0.0010.052
p-Value 20.013< 0.001< 0.0010.4< 0.0010.083

DNMT1a

rs2228612 (in LD with rs10845076)

 GG2112.77.577.12011.99.976.7
 GA629.87.880.4123139.774.6
 AA8811878.9217149.873.5
p-Value 10.130.880.170.170.890.42
p-Value 20.170.90.230.0280.890.4

DNMT3b

rs6087990

 TT3413.710.673.8
 TC1912.18.676.914512.59.875.8
 CC15010.57.879.618014.59.772.6
p-Value 10.120.120.0590.0150.330.007
p-Value 20.320.0990.120.0300.330.013

rs2424913

 CC2612.510.275.5
 CT1711.787813312.69.875.6
 TT15310.67.879.420014.39.772.8
p-Value 10.240.490.250.0370.640.020
p-Value 20.450.480.420.0440.640.021

%iAs and %MMA are both geometric means, whereas the %DMA is an arithmetic mean.

The AS3MT genotype associated with a low %MMA and a high %DMA in Argentina is listed first.

p-Value 1 for genotype coefficients (coded as categorical variables according to the number of variant alleles) from multivariate regression models for each population and outcome [ln(%iAs), ln(%MMA), or %DMA in Argentina or Bangladesh] adjusted for ln(U-As) only; the models were not used to derive mean values for the metabolites.

p-Value 2 for genotype coefficients (coded as categorical variables) from multivariate regression models for each location and outcome with adjustment for ln(U-As) and the following covariates: for Argentina ln(%iAs): coca use, age, parity; Argentina ln(%MMA): coca use, BMI, parity; Argentina %DMA: coca use, BMI, age, parity; Bangladesh ln(%iAs) and %DMA: age, BMI. Models used to test associations with ln(%MMA) in Bangladesh were adjusted for ln(U-As) only because none of the other variables tested had a p < 0.2 in the univariate model. Models were used for hypothesis testing only and were not used to derive mean values for the metabolites.

Polymorphisms in AS3MT LD cluster # 1 in Bangladesh.

Polymorphisms in LD cluster # 2.

In both populations, participants possessing one or two copies of haplotype 1 had higher %MMA than did those who did not carry this haplotype (Table 3). Haplotype 1 was the most common haplotype in Bangladesh (52%). Haplotype 2 was associated with lower %iAs, lower %MMA, and higher %DMA in both populations (although %MMA was not statistically significant in Bangladesh) and was more frequent in Argentina (70%) than in Bangladesh (16.5%). Haplotype 3 was significantly associated with lower %MMA, but this haplotype was present almost exclusively in Bangladesh (16.5%). Haplotype 4 was associated with higher %iAs and lower %DMA in both populations, although this was statistically significant only in Bangladesh. This was the only haplotype containing the C-allele of rs11191439, and we found no individuals with two copies of this haplotype in either population.
Table 3

Observed percentages of As metabolites according to copy number (zero, one, or two) of the common AS3MT haplotypes.

Argentina
Bangladesh
Haplotype/sequencea0 copies1 copy2 copiesp-Valueb0 copies1 copy2 copiesp-Valueb
1. AAGGTTGT

n (%)97 (57)60 (35)15 (9)79 (22)192 (53)90 (25)
 Geometric mean %iAs9.511.914.20.01514.113.214.00.66
 Geometric mean %MMA7.18.610.30.0018.710.210.00.006
 Mean %DMA81.477.573.5< 0.00174.174.273.60.97

2. GCCATCAC

n (%)17 (10)71 (41)84 (49)255 (71)95 (26)11 (3)
 Geometric mean %iAs14.712.09.00.00114.212.211.30.027
 Geometric mean %MMA10.08.76.8< 0.00110.09.57.80.16
 Mean %DMA73.377.382.2< 0.00172.976.479.40.005

3. ACGGTTAC

n (%)171 (99.4)1 (0.6)250 (69)104 (29)7 (2)
 Geometric mean %iAsNANANA13.314.311.40.16
 Geometric mean %MMANANANA10.38.78.0< 0.001
 Mean %DMANANANA74.273.478.70.16

4. GCGGCTAT

n (%)166 (96)6 (4)322 (89)39 (11)
 Geometric mean %iAs10.712.60.2713.217.10.002
 Geometric mean %MMA7.710.20.279.611.10.088
 Mean %DMA79.475.40.4574.768.2< 0.001

Abbreviations: n, number of individuals; NA, not applicable (no or very few individuals with that haplotype).

Polymorphisms are listed in 5′ to 3′ direction: rs7085104, rs3740400, rs3740393, rs3740390, rs11191439, rs11191453, rs10748835, and rs1046778. Only haplotypes with a frequency > 5% in any population are included; for individuals with missing data for one or more polymorphisms, the missing alleles were inferred using PHASE.

p-Values for haplotype coefficients (coded as categorical variables according to the number of copies of the haplotype) from regression models for each population and outcome [ln(%iAs), ln(%MMA), or %DMA in Argentina or Bangladesh] adjusted for ln(U-As) only. The models were not used to derive mean values for the metabolite; models with adjustments for other influential variables (see information for p-value 2 Table 2 footnote d) were also evaluated, but the p-values were very similar when adjusting for ln(U-As) only (data not shown).

AS3MT expression analysis

Heterozygous and homozygous genotypes that included alleles associated with high %MMA and low %DMA among the women in Argentina were associated with higher AS3MT expression than were corresponding reference genotypes associated with low %MMA and high %DMA. Associations were statistically significant for rs3740400 based on assay 1 (observed gene expressions for the AA and CA genotypes were 240% and 220% higher, respectively, than for the CC genotype; p = 0.009) and for rs1046778 based on assay 4 (observed gene expressions for the TT and CT genotypes were 69% and 36%, respectively, higher than for the CC genotype; p = 0.008) (Figure 1); the p-values for the other assays were 0.18 (for rs3740393 based on assay 2) and 0.077 (for rs3740390 based on assay 3). We ran both endogenous control genes for all assays. The results were very similar when using HPRT1 or TBP as endogenous controls, but the HPRT1 gene demonstrated less variability (the coefficient of variance was 22% for HPRT1 vs. 32% for TBP). We found no association between the AS3MT rs1046778 polymorphism and expression of the downstream gene CNNM2 (p = 0.82). Carriers of each genotype demonstrated a similar expression pattern for all AS3MT gene segments analyzed, and we found no evidence that a certain genotype caused alternative splicing. We repeated the gene expression analysis based on assay 4 on a larger set of individuals (n = 55) and observed the same pattern: relative to the rs1046778 CC genotype, AS3MT expression was 175% and 80% higher among those with rs1046778 TT and CT genotypes, respectively (p < 0.001; Figure 1). Among these 55 individuals, expression of AS3MT (assay 4) was positively (but not significantly) associated with %iAs (rs = 0.16, p = 0.24) and %MMA (rs = 0.18, p = 0.18) and inversely associated with %DMA (rs = −0.28, p = 0.090).
Figure 1

Box plots depicting relative AS3MT gene expression according to genotype in women from Argentina; expression for the reference genotype (associated with low %MMA and high %DMA) is set to 1. (A) Relative gene expression based on assay 1 (covering exons 1–2) according to rs3740400 genotype. (B) Relative gene expression based on assay 4 (covering part of the 3′ untranslated region) according to rs1046778 genotype. Numbers below the boxes indicate the number of individuals with that genotype. The bottom and top of each box indicate 25th and 75th percentiles, respectively; the line inside the box is the median; whiskers represent the smallest and the largest values that are not outliers. Circles and asterisks indicate outliers; squares indicate outliers outside the range of the y-axis, which had a gene expression of 25 (CT genotype) and 23 (TT genotype).

DNMT1a and DNMT3b.

The minor allele frequencies for the five polymorphisms analyzed in DNMT1a were 4–40% in Argentina and 2–44% in Bangladesh, whereas the minor allele frequencies for the three polymorphisms analyzed in DNMT3b were 5–6% in Argentina and 23–44% in Bangladesh [see Supplemental Material, Table 1 (doi:10.1289/ehp.1002471)]. The LD pattern for the DNMT genes was similar in Bangladesh and Argentina. The rs10854076 and rs2228612 polymorphisms in DNMT1a showed strong LD in both populations (R2 = 0.99 in Argentina, 0.84 in Bangladesh), whereas the R2 values between the other polymorphisms in DNMT1a were rather low. All DNMT3b polymorphisms showed LD in both study populations, with R2 values ranging from 0.39 to 0.79 in Bangladesh and from 0.88 to 1 in Argentina. We found no significant associations between DNMT polymorphisms and As metabolism among the Argentinean women. However, four DNMT polymorphisms were significantly associated with metabolite patterns among women in Bangladesh (Table 2): The DNMT1a polymorphisms rs2228612 and rs10845076 (in complete LD) predicted %iAs (p = 0.028, highest for the common rs2228612 AA variant), whereas the DNMT3b polymorphisms rs6087990 and rs2424913 predicted %iAs (p = 0.030 and 0.044, highest for the common rs6087990 CC and rs2424913 TT genotypes, respectively) and %DMA (p-values = 0.013 and 0.021, respectively, with lower mean values for the CC and TT genotypes). We observed no significant associations with metabolite patterns in either population for DNMT1a rs2228611, rs16999593, or rs7253062 or for DNMT3b rs2424932 (data not shown).

PEMT and BHMT.

For PEMT, rs1531100 and rs4244598 showed LD for both populations (R2 = 0.70 in Bangladesh and 1 in Argentina), but rs2278952 and rs897453 showed no LD with any other PEMT polymorphism evaluated. The two BHMT polymorphisms showed no LD. Polymorphisms in PEMT or BHMT were not statistically significant predictors of As metabolite patterns.

Discussion

This study demonstrated strong associations between AS3MT polymorphisms and As metabolism in two populations, one from the Argentinean Andes and one from Bangladesh, both of which are heterogeneous in genetic background and in living conditions. The finding of two LD clusters with different patterns of metabolite fractions suggests the presence of several influential polymorphisms along the gene. Noncoding polymorphisms in AS3MT were significantly associated with altered gene expression. In addition, four polymorphisms in DNMT1a and DNMT3b were associated with As metabolites among the pregnant women from Bangladesh. One strength of this study is that both populations had wide ranges of both total U-As and As metabolites. Also, the study subjects within each population were rather homogeneous regarding social status and food habits. However, the populations differed from each other in a number of ways, not only genetically but also regarding food habits, nutritional status, lifestyle factors, and pregnancy (all women from Bangladesh were in early pregnancy). This strengthens the hypothesis that the impact of AS3MT on As metabolite pattern should be valid for people worldwide and not strongly modified by environmental or biological factors. We are aware that relatively few individuals were included in the gene expression analyses. Nevertheless, genotype was highly predictive of the gene expression of AS3MT. This was apparent despite the fact that gene expression was measured in peripheral blood, which has a lower expression of AS3MT than in the main As-methylating tissues, that is, liver and kidney (Su et al. 2004). We used blood as a proxy for liver because sampling liver tissues is a difficult and invasive procedure. It is, however, important to note that extrapolation of gene expression from blood to liver is difficult because of tissue-specific differences in transcription factors and other regulating elements, as well as differences in metabolite distributions between blood and liver, that may affect the result. Six polymorphisms were associated with As metabolite pattern in subjects from both Argentina and Bangladesh. Several AS3MT polymorphisms were associated with %iAs, which we did not detect in our earlier studies in Argentina (Schläwicke Engström et al. 2007, 2009), possibly due to a lower power in those studies (which included about 100 fewer individuals). We confirmed associations between six AS3MT polymorphisms and As metabolism observed in our earlier studies in another group of individuals from the same region in Argentina (Schläwicke Engström et al. 2007, 2009). Additionally, two polymorphisms not investigated in any of our earlier studies (rs11191453 and rs1046778) significantly predicted the metabolite pattern. Because many polymorphisms showed strong LD and because the significance levels are dependent on the genotype frequencies, it is not possible to attribute causal effects to specific variants. However, in Bangladesh we observed associations with %MMA mainly for polymorphisms in cluster 1 (rs3740400, rs10748835, and rs1046778), which are situated in the 5′ and the 3′ end of the gene, whereas we observed associations with %iAs and %DMA mainly for polymorphisms in cluster 2 (rs3740393, rs3740390, and rs11191453), which are situated in the middle and the 3′ end of the gene. We confirmed previous findings of a higher %MMA and lower %DMA in association with the Thr allele in Met287Thr (rs111191439) (Hernandez et al. 2008; Lindberg et al. 2007b; Valenzuela et al. 2009). The Thr allele in Met287Thr has also been associated with a marginally higher risk (p = 0.055) of premalignant skin lesions (Valenzuela et al. 2009). This polymorphism had rather low frequencies in the populations studied, which were from Chile (Hernandez et al. 2008), Eastern Europe (Lindberg et al. 2007b), and Mexico (Valenzuela et al. 2009), where the allele frequencies were around 5–10%. The fact that the women from Bangladesh were in early pregnancy may have had an impact on the association between polymorphisms in methyltransferases and As metabolite patterns. Pregnancy is known to induce methylation reactions required for tissue growth and development, as well as As methylation (Concha et al. 1998; Szyf 2009), which may have obscured associations with polymorphisms in methyltransferase genes among the women in Bangladesh. However, to determine the effect of pregnancy on the associations between genotype and As metabolite pattern, pregnant and nonpregnant women from the same population should be compared, or a study with repeated sampling during pregnancy could be performed. The frequencies of the AS3MT polymorphisms associated with As metabolism deviated markedly between the Argentinean and Bangladeshi populations. In the Argentinean population, the alleles and haplotypes associated with more efficient methylation were very frequent, which is interesting considering the fact that the indigenous people have been living in this As-contaminated area for many generations (Figueroa et al. 1992), suggesting a selection for genotypes associated with efficient As metabolism. In Bangladesh, where most of the tube wells have been installed in the last 20–40 years, the alleles associated with more efficient methylation were the least common; nevertheless, allele frequencies were rather high (~ 45%) for the polymorphisms in LD cluster 1. Still, the general evidence of associations between AS3MT genotype on the As metabolite fraction was similar in both populations. The present study, as well as other studies (Agusa et al. 2009; Hernandez et al. 2008; Lindberg et al. 2007b; Meza et al. 2005), strongly support a causal association of AS3MT genotype on As metabolism worldwide. A higher %MMA is linked to several adverse health effects (Hsueh et al. 1997; Lindberg et al. 2008; Tseng 2007; Yu et al. 2000). Individuals in Bangladesh who had an MMA level > 8% had a significantly higher risk (p < 0.01) for skin lesions compared with the reference group (where %MMA was < 8) (Lindberg et al. 2008). As demonstrated here, AS3MT genotypes significantly predict the fraction of metabolites and may explain part of the individual differences in the fraction of MMA detected and, in turn, explain differences in susceptibility to skin lesions. Thus, AS3MT genotype is probably a susceptibility factor for As toxicity, and the allelic distribution of AS3MT polymorphisms should be taken into account in future risk evaluations of As in drinking water and food. In the present study, we demonstrate for the first time that noncoding AS3MT polymorphisms were associated with AS3MT gene expression levels. The common homozygotes in the Argentinean population were associated with lower %MMA and higher %DMA and were also associated with lower AS3MT expression relative to other genotypes. We could not determine whether associations were causal effects due to a single AS3MT polymorphism or a specific haplotype, because all polymorphisms, spread throughout the gene, showed strong LD in Argentina. However, polymorphisms in the 5′ part of the gene (assay 1, 5′ of rs3740400) and 3′ untranslated region (assay 4, including rs1046778), which are likely to involve regulatory sequences, were significantly associated with gene expression. In addition, expression was also associated, although not significantly, with metabolite patterns in urine. We saw no indications that the genotype influenced the splicing of the gene, because we observed a similar pattern of gene expression for all four gene segments analyzed. Wood et al. (2006) evaluated the potential impact of polymorphisms on AS3MT protein levels in vitro, where the transient expression of the wild-type AS3MT sequence and the variant allozyme of Met287Thr were evaluated in COS-1 monkey kidney cells. Endogenous activity of untransfected COS-1 cells was negligible. The 287Thr allozyme, which has been associated with a higher %MMA and lower %DMA, had higher in vitro protein levels than did those of the wild type. In the present study, very few Argentinean subjects possessed the Thr allele, so it was not possible to evaluate whether this polymorphism was associated with AS3MT gene expression. However, for the polymorphisms that we included in the gene expression analyses, the alleles associated with higher %MMA and lower %DMA were associated with higher gene expression, similar to the association between the 287Thr allele, linked to higher %MMA and lower %DMA, and higher in vitro protein levels. Gene expression and protein levels are not always correlated because posttranscriptional regulation processes may be involved. Further studies are needed to evaluate the impact of polymorphisms on the protein level. We observed associations with DNMT polymorphisms in Bangladesh only, and these results need to be confirmed. DNMT1a rs16999593 was previously associated with lower %DMA in Argentina (Schläwicke Engström et al. 2009), but this association was not evident in the present study population. However, some of the DNMT polymorphisms had a very low allele frequency in Argentina.

Conclusions

Polymorphisms in AS3MT significantly predicted As metabolism in these two very different populations, which suggests that an effect of AS3MT on As metabolite pattern may be present in populations worldwide. AS3MT polymorphisms were also associated with AS3MT expression in peripheral blood, such that polymorphisms associated with efficient methylation were associated with reduced expression of the AS3MT gene. Evidence of an effect of the polymorphisms is of importance for risk assessment of As, because a low methylation efficiency is associated with increased risk for As toxicity.
  30 in total

1.  Some drinking-water disinfectants and contaminants, including arsenic.

Authors: 
Journal:  IARC Monogr Eval Carcinog Risks Hum       Date:  2004

2.  Evaluation of the three most commonly used analytical methods for determination of inorganic arsenic and its metabolites in urine.

Authors:  Anna-Lena Lindberg; Walter Goessler; Margaretha Grandér; Barbro Nermell; Marie Vahter
Journal:  Toxicol Lett       Date:  2006-11-16       Impact factor: 4.372

Review 3.  Biomarkers of exposure, effect, and susceptibility of arsenic-induced health hazards in Taiwan.

Authors:  Chien-Jen Chen; Lin-I Hsu; Chih-Hao Wang; Wei-Liang Shih; Yi-Hsiang Hsu; Mei-Ping Tseng; Yu-Chun Lin; Wei-Ling Chou; Chia-Yen Chen; Cheng-Yeh Lee; Li-Hua Wang; Yu-Chin Cheng; Chi-Ling Chen; Shu-Yuan Chen; Yuan-Hung Wang; Yu-Mei Hsueh; Hung-Yi Chiou; Meei-Maan Wu
Journal:  Toxicol Appl Pharmacol       Date:  2005-08-07       Impact factor: 4.219

4.  Arsenic exposure in pregnancy: a population-based study in Matlab, Bangladesh.

Authors:  Marie E Vahter; Li Li; Barbro Nermell; Anisur Rahman; Shams El Arifeen; Mahfuzar Rahman; Lars Ake Persson; Eva-Charlotte Ekström
Journal:  J Health Popul Nutr       Date:  2006-06       Impact factor: 2.000

5.  Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies.

Authors:  Thomas C Wood; Oreste E Salavagionne; Baidehi Mukherjee; Liewei Wang; Annette F Klumpp; Bianca A Thomae; Bruce W Eckloff; Daniel J Schaid; Eric D Wieben; Richard M Weinshilboum
Journal:  J Biol Chem       Date:  2006-01-06       Impact factor: 5.157

Review 6.  Arsenic methylation, urinary arsenic metabolites and human diseases: current perspective.

Authors:  Chin-Hsiao Tseng
Journal:  J Environ Sci Health C Environ Carcinog Ecotoxicol Rev       Date:  2007 Jan-Mar       Impact factor: 3.781

7.  Interindividual variation in the metabolism of arsenic in cultured primary human hepatocytes.

Authors:  Zuzana Drobná; Stephen B Waters; Felecia S Walton; Edward L LeCluyse; David J Thomas; Miroslav Stýblo
Journal:  Toxicol Appl Pharmacol       Date:  2004-12-01       Impact factor: 4.219

8.  Developmentally restricted genetic determinants of human arsenic metabolism: association between urinary methylated arsenic and CYT19 polymorphisms in children.

Authors:  Maria Mercedes Meza; Lizhi Yu; Yelitza Y Rodriguez; Mischa Guild; David Thompson; A Jay Gandolfi; Walter T Klimecki
Journal:  Environ Health Perspect       Date:  2005-06       Impact factor: 9.031

9.  Spatial and temporal variations in arsenic exposure via drinking-water in northern Argentina.

Authors:  Gabriela Concha; Barbro Nermell; Marie Vahter
Journal:  J Health Popul Nutr       Date:  2006-09       Impact factor: 2.000

10.  Genetic polymorphisms influencing arsenic metabolism: evidence from Argentina.

Authors:  Karin Schläwicke Engström; Karin Broberg; Gabriela Concha; Barbro Nermell; Margareta Warholm; Marie Vahter
Journal:  Environ Health Perspect       Date:  2007-01-08       Impact factor: 9.031

View more
  67 in total

1.  ATP13A2 (PARK9) polymorphisms influence the neurotoxic effects of manganese.

Authors:  Gerda Rentschler; Loredana Covolo; Amelia Ahmadi Haddad; Roberto G Lucchini; Silvia Zoni; Karin Broberg
Journal:  Neurotoxicology       Date:  2012-01-20       Impact factor: 4.294

2.  Interactive Influence of N6AMT1 and As3MT Genetic Variations on Arsenic Metabolism in the Population of Inner Mongolia, China.

Authors:  Xushen Chen; Xiaojuan Guo; Ping He; Jing Nie; Xiaoyan Yan; Jinqiu Zhu; Luoping Zhang; Guangyun Mao; Hongmei Wu; Zhiyue Liu; Diana Aga; Peilin Xu; Martyn Smith; Xuefeng Ren
Journal:  Toxicol Sci       Date:  2016-09-16       Impact factor: 4.849

3.  Mendelian randomization of inorganic arsenic metabolism as a risk factor for hypertension- and diabetes-related traits among adults in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) cohort.

Authors:  Molly Scannell Bryan; Tamar Sofer; Yasmin Mossavar-Rahmani; Bharat Thyagarajan; Donglin Zeng; Martha L Daviglus; Maria Argos
Journal:  Int J Epidemiol       Date:  2019-06-01       Impact factor: 7.196

4.  Analysis of maternal polymorphisms in arsenic (+3 oxidation state)-methyltransferase AS3MT and fetal sex in relation to arsenic metabolism and infant birth outcomes: Implications for risk analysis.

Authors:  Zuzana Drobná; Elizabeth Martin; Kyung Su Kim; Lisa Smeester; Paige Bommarito; Marisela Rubio-Andrade; Gonzalo G García-Vargas; Miroslav Stýblo; Fei Zou; Rebecca C Fry
Journal:  Reprod Toxicol       Date:  2016-02-27       Impact factor: 3.143

5.  Effects of reduced mitochondrial DNA content on secondary mitochondrial toxicant exposure in Caenorhabditis elegans.

Authors:  Anthony L Luz; Joel N Meyer
Journal:  Mitochondrion       Date:  2016-08-23       Impact factor: 4.160

6.  Association between polymorphisms in arsenic metabolism genes and urinary arsenic methylation profiles in girls and boys chronically exposed to arsenic.

Authors:  Rogelio Recio-Vega; Tania González-Cortes; Edgar Olivas-Calderón; R Clark Lantz; A Jay Gandolfi; Gladis Michel-Ramirez
Journal:  Environ Mol Mutagen       Date:  2016-06-21       Impact factor: 3.216

7.  Differential methylation of the arsenic (III) methyltransferase promoter according to arsenic exposure.

Authors:  Matthew O Gribble; Wan-Yee Tang; Yan Shang; Jonathan Pollak; Jason G Umans; Kevin A Francesconi; Walter Goessler; Ellen K Silbergeld; Eliseo Guallar; Shelley A Cole; M Daniele Fallin; Ana Navas-Acien
Journal:  Arch Toxicol       Date:  2013-10-24       Impact factor: 5.153

8.  Environmental exposure to arsenic, AS3MT polymorphism and prevalence of diabetes in Mexico.

Authors:  Zuzana Drobná; Luz M Del Razo; Gonzalo G García-Vargas; Luz C Sánchez-Peña; Angel Barrera-Hernández; Miroslav Stýblo; Dana Loomis
Journal:  J Expo Sci Environ Epidemiol       Date:  2012-10-24       Impact factor: 5.563

9.  Methylarsonous acid causes oxidative DNA damage in cells independent of the ability to biomethylate inorganic arsenic.

Authors:  Erik J Tokar; Chikara Kojima; Michael P Waalkes
Journal:  Arch Toxicol       Date:  2013-10-05       Impact factor: 5.153

10.  Gene-arsenic interaction in longitudinal changes of blood pressure: Findings from the Health Effects of Arsenic Longitudinal Study (HEALS) in Bangladesh.

Authors:  Shohreh F Farzan; Margaret R Karagas; Jieying Jiang; Fen Wu; Mengling Liu; Jonathan D Newman; Farzana Jasmine; Muhammad G Kibriya; Rachelle Paul-Brutus; Faruque Parvez; Maria Argos; Molly Scannell Bryan; Mahbub Eunus; Alauddin Ahmed; Tariqul Islam; Muhammad Rakibuz-Zaman; Rabiul Hasan; Golam Sarwar; Vesna Slavkovich; Joseph Graziano; Habibul Ahsan; Yu Chen
Journal:  Toxicol Appl Pharmacol       Date:  2015-07-26       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.